Consumers Injury Help
Oxbryta Lawsuit

Oxbryta Lawsuit

If you or a loved one were prescribed Oxbryta for Sickle Cell Disease and suffered serious complications, you may be entitled to SIGNIFICANT compensation. Pfizer withdrew Oxbryta from the market in 2024 after evidence of life-threatening risks emerged.

Get A Free Case Review
Active Litigation — Pfizer / Oxbryta Withdrawal 2024

ATTENTION: OXBRYTA PATIENTS

If you or a loved one took Oxbryta for Sickle Cell Disease and experienced serious complications, you may be entitled to SIGNIFICANT compensation!

Oxbryta was withdrawn from the market in 2024 after clinical evidence revealed it may increase the risk of serious complications — including stroke, organ failure, and death — while masking disease progression.

Find Out if You Qualify

SIGNIFICANT Compensation May Be Available

Were you or a loved one prescribed OXBRYTA® for Sickle Cell Disease?

Did you or a loved one experience any serious complications while on OXBRYTA®?

Do you already have an attorney regarding Oxbryta?

LARGE SETTLEMENT AMOUNT

COULD BE CLAIMED

How do we help YOU?

Oxbryta (voxelotor) was developed by Pfizer to treat sickle cell disease and was FDA-approved in 2019. It was withdrawn from the market in 2024 after evidence emerged showing it may actually increase life-threatening complications — including stroke, acute chest syndrome, and death — while masking the underlying disease.

How does filing a claim work?

  • 1. Fill out our simple form. Or call to make your claim immediately.
  • 2. Get a FREE case review from our expert partners.
  • 3. We fight on your behalf for the highest compensation possible.
  • 4. Claim your settlement!
  • Remember: you only pay if you get a settlement! Our service is totally RISK FREE.

Oxbryta improved lab results — but increased serious complications and death in sickle cell patients.

While Oxbryta appeared to improve hemoglobin levels on paper, clinical data revealed patients experienced higher rates of dangerous complications compared to those not on the drug. Pfizer withdrew Oxbryta from the market in 2024 — but only after thousands of sickle cell patients had already been harmed.

What Is the Oxbryta Lawsuit?

Oxbryta (voxelotor), manufactured by Pfizer, was an FDA-approved treatment for sickle cell disease. It was withdrawn from the market in 2024 after evidence emerged that it may increase the risk of serious complications — including vaso-occlusive crises, stroke, organ failure, and death — while providing misleading lab result improvements.

Lawsuits allege Pfizer failed to adequately warn patients and physicians of these risks, and that the drug was marketed based on surrogate endpoints (improved hemoglobin levels) that did not translate into clinical benefit.

Who Qualifies for an Oxbryta Lawsuit?

Patients prescribed Oxbryta® for sickle cell disease who experienced increased vaso-occlusive crises, stroke, organ failure, acute chest syndrome, disabling pain crises, splenic complications, or death may be eligible to file a claim.

Were you or a loved one harmed by Oxbryta?

Get A Free Case Review

Serious Complications Linked to Oxbryta

  • Increased vaso-occlusive crises (VOC) — painful and dangerous blood flow blockages
  • Stroke — sudden and potentially fatal brain injury
  • Organ failure — including kidney failure requiring dialysis
  • Acute chest syndrome — a life-threatening lung complication
  • Splenic pooling and spleen removal — surgical intervention required
  • Disabling pain crises — requiring emergency hospitalization
  • Arthritis — joint pain and inflammation
  • Death

Why Was Oxbryta Withdrawn?

Pfizer withdrew Oxbryta from the market in 2024 after clinical data revealed that while the drug improved hemoglobin levels — creating the appearance of benefit — patients experienced a higher rate of serious complications and deaths compared to those not on the drug.

Critics allege the drug was approved based on surrogate endpoints that masked the true clinical picture. Lawsuits claim Pfizer knew or should have known about these risks and failed to adequately disclose them to patients and healthcare providers.

Oxbryta Lawsuit Timeline and Settlements

Oxbryta was withdrawn from the market in 2024. Litigation is in early stages with cases being actively evaluated. Settlement amounts will depend on the severity of complications, hospitalization history, long-term health impacts, and other factors.

Act promptly — filing deadlines apply. Contact a legal expert today at no cost to you.